Switzerland-based Novartis (NOVN: VX) has won European approval for the one-time gene therapy Luxturna (voretigene neparvovec). The treatment was approved in the USA in late December 2017.
The drug has been approved to treat vision loss due to a genetic mutation in both copies of the RPE65 gene, for people who have enough viable retinal cells.
Luxturna was developed and is commercialized in the USA by Spark Therapeutics (Nasdaq: ONCE). The firm agreed terms with Novartis in January for an ex-US commercialization deal, worth over $100 million up front, and up to $170 million in total.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze